Should you buy Mesoblast, Paladin Energy, and Xero shares?

If you are on the lookout for some new portfolio additions, then read on.

That’s because analysts have just given their verdicts on three popular options.

Here’s what they are saying about these ASX shares courtesy of The Bull:

Mesoblast Ltd (ASX: MSB)

The team at Securities Vault is positive on this allogenic cellular medicines developer and has named it as a buy.

It highlights that its commercialisation strategy is progressing and its development pipeline is strong. It said:

Mesoblast develops allogenic cellular medicines for treating severe and life threatening inflammatory conditions.This regeneration therapy company offers growth momentum. Mesoblast’s lead product Ryoncil achieved meaningful revenue growth and now benefits from favourable reimbursement codes in the United States.

The company holds a strong cash position of about $US145 million and offers flexibility via a $US50 million convertible note facility to fund the next growth phase. Company commercialisation is progressing and MSB has generated a pipeline of depth.

Paladin Energy Ltd (ASX: PDN)

Analysts at Ord Minnett believe that this uranium miner’s shares have risen too strongly in recent times. And while its performance has been positive, this isn’t enough to justify its valuation. As a result, they have put a sell rating on the stock.

This uranium producer owns 75 per cent of the Langer Heinrich mine in Namibia. It also owns uranium exploration and development assets in Australia and Canada. The company delivered record production in the September quarter, but sales volumes fell on the previous quarter and prior corresponding period.  Despite a decent result, PDN’s share price recently doubled in the past six months and has outpaced its fundamentals.

Xero Ltd (ASX: XRO)

The team at MPC Markets has named this cloud accounting platform provider as a hold.

It notes that it has a significant opportunity in the United States, but points out that small to medium sized enterprises are under pressure. It said:

XRO is a global accounting software provider. The company delivered operating revenue of $NZ1.194 billion for the six months ending September 30, 2025, up 20 per cent on the prior corresponding period. Net profit after tax of $NZ134.78 million was up 42 per cent. The company completed an institutional placement of $1.85 billion in June to fund the company’s acquisition of Melio, a US business-to-business payments platform.

The US is a key expansion market for future earnings, but small to medium sized enterprises are under pressure. The shares have fallen from $194.21 on June 24 to trade at $121.18 on November 19. At these levels, investors can continue to hold, but should monitor developments, particularly in the US.

The post Should you buy Mesoblast, Paladin Energy, and Xero shares? appeared first on The Motley Fool Australia.

More reading

• 2 great ASX 200 blue-chip shares I’d buy right now
• These are the 10 most shorted ASX shares
• Top brokers name 3 ASX shares to buy next week
• Why are ASX 200 tech stocks getting smashed on Friday?
• 3 ASX 200 shares that could be top buys for growth

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.